Table 3.

MRI outcomes at Week 12 and Week 24.

Placebo, n = 48Baricitinib
1 mg, n = 272 mg, n = 294 mg, n = 268 mg, n = 24
Week 12
  Patients with improvement in synovitis, n (%)6 (13)9 (33)4 (14)8 (31)7 (29)
  Uninvolved joints that developed new synovitis, mean %3.52.50.71.34.7
  Patients with improvement in osteitis, n (%)5 (10)7 (26)7 (24)6 (23)6 (25)
  Uninvolved bones that developed new osteitis, mean %2.11.92.22.32.5
  Patients with no worsening in bone erosion, n (%)31 (79)22 (88)26 (90)24 (96)21 (88)
  Uninvolved bones that developed new bone erosion, mean %2.70.30.60.91.1
  Patients with no worsening in cartilage loss, n (%)37 (95)25 (100)29 (100)25 (100)24 (100)
  Uninvolved joints that developed new cartilage loss, mean %1.10.20.00.00.2
Week 24
  Patients with improvement in synovitis, n (%)4 (8)7 (26)5 (17)8 (31)8 (33)
  Uninvolved joints that developed new synovitis, mean %3.52.52.26.42.6
  Patients with improvement in osteitis, n (%)5 (10)8 (30)6 (21)8 (31)6 (25)
  Uninvolved bones that developed new osteitis, mean %2.11.92.11.82.4
  Patients with no worsening in bone erosion, n (%)30 (77)19 (76)24 (83)24 (96)23 (96)
  Uninvolved bones that developed new bone erosion, mean %2.70.30.90.22.3
  Patients with no worsening in cartilage loss, n (%)35 (90)23 (92)27 (93)25 (100)24 (100)
  Uninvolved joints that developed new cartilage loss, mean %1.10.21.00.00.4
  • Improvement in synovitis and in osteitis was defined as a change from baseline that exceeded the SDC. No worsening in bone erosion and in cartilage loss was defined as a change from baseline < SDC. Placebo and baricitinib 1-mg groups at Week 24 were imputed using last observation carried forward for synovitis and osteitis and using linear extrapolation for bone erosion and cartilage loss from baseline and Week 12 scores. MRI: magnetic resonance imaging; SDC: smallest detectable change.